Marcia Belvin - 20 Sep 2023 Form 4 Insider Report for CytomX Therapeutics, Inc. (CTMX)

Role
SVP, Chief Scientific Officer
Signature
/s/ Lloyd Rowland, as Attorney-in-Fact for Marcia Belvin
Issuer symbol
CTMX
Transactions as of
20 Sep 2023
Net transactions value
-$5,356
Form type
4
Filing time
22 Sep 2023, 19:16:52 UTC
Previous filing
29 Mar 2023
Next filing
19 Dec 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CTMX Common Stock Award $0 +11,250 +8% $0.000000 152,070 20 Sep 2023 Direct F1, F2
transaction CTMX Common Stock Sale $5,356 -4,119 -2.7% $1.30 147,951 22 Sep 2023 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents Performance Stock Units ("PSUs") initially granted on October 24, 2021 that were subject to a performance-based vesting condition. The second milestone vesting condition was determined to be satisfied upon which the remaining 50% of the PSUs vested.
F2 Includes 116,875 restricted stock units.
F3 The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of PSUs.